---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009649"
form_type: "8-K"
ticker: "KURA"
cik: "0001422143"
company_name: "Kura Oncology, Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:49:30.863840+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Kura Oncology reports $2.1M KOMZIFTI net revenue in first 5 weeks post-launch; cash at $667M

## Summary
- $2.1M KOMZIFTI net product revenue from Nov 21 to Dec 31, 2025 (first commercial sales).
- $195M milestone payment from Kyowa Kirin in Q4 2025; non-cash collaboration revenue $15-17M.
- Cash, cash equivalents & short-term investments $667.3M as of Dec 31, 2025.
- KOMZIFTI granted full FDA approval in Nov 2025 for R/R NPM1-mutated AML; NCCN Category 2A.
- 2026 guidance: non-cash collaboration revenue $45-55M; pipeline milestones include Phase 3 trial enrollment.

## SEC filing metadata
- accession: 0001193125-26-009649
- form_type: 8-K
- ticker: KURA
- cik: 0001422143
- company_name: Kura Oncology, Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1422143/000119312526009649/0001193125-26-009649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1422143/000119312526009649/d55582d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009649
- JSON: https://secwatch.observer/filing/0001193125-26-009649.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.